In Vivo: BMS-820132 (compound 31) (3 μmol/kg, 30 μmol/kg; po; single dose) decreases glucose levels in high-fat diet-induced obese (DIO) mice, in an oral glucose tolerance test (OGTT). BMS-820132 (10-200 mg/kg; po; once daily for 1 mo) results in body weight reduction in normal rat but not ZDF rats, indicating that the toxicity is secondary to the exaggerated pharmacology of potent GK activation. BMS-820132 (10 mg/kg, 60 mg/kg, 120 mg/kg; po; once daily for 1 mo) results insignificant effects on dogs food consumption.